ISSN 1866-8836
Клеточная терапия и трансплантация

Change template to: full
Volume 9, Number 4
Volume 9, Number 4
Kulagin A. D. (St. Petersburg, Russia)
Wagemaker G. (Rotterdam, Netherlands)
Zander A. R. (Hamburg, Germany)
Deputy Editor
Fehse B. (Hamburg, Germany)
Managing Editor
Chukhlovin A. B. (St. Petersburg, Russia)
Editorial Board
Aleynikova O. V. (Minsk, Republic of Belarus)
Borset M. (Trondheim, Norway)
Chechetkin A. V. (St. Petersburg, Russia)
Fibbe W. (Leiden, Netherlands)
Galibin O. V. (St. Petersburg, Russia)
Hölzer D. (Frankfurt a.M., Germany)
Klimko N. N. (St. Petersburg, Russia)
Kolb H.-J. (München, Germany)
Kröger N. (Hamburg, Germany)
Lange C. (Hamburg, Germany)
Mamaev N. N. (St. Petersburg, Russia)
Mikhailova N. B. (St. Petersburg, Russia)
Moiseev I. S. (St. Petersburg, Russia)
Nagler A. (Tel-Aviv, Israel)
Nemkov A. S. (St. Petersburg, Russia)
Paramonov I. V. (Kirov, Russia)
Roumiantsev A. G. (Moscow, Russia)
Savchenko V. G. (Moscow, Russia)
Smirnov A. V. (St. Petersburg, Russia)
Uss A. L. (Minsk, Republic of Belarus)
Zubarovskaya L. S. (St. Petersburg, Russia)
In this Issue

Dear CTT authors and readers,

Despite great advances made in targeted treatments of blood cancer, we are still facing a lot of cases, in which these methods are not efficient or safe enough. Аllogeneic hematopoietic stem cell transplantation (allo-HSCT), an old method with proven efficacy, is still required to change the course of the disease. For this, chronic myeloid leukemia (CML) may be the most obvious showcase.

For the last 150 years CML has been among most studied hematological malignancies. It was the first hematological disorder with marker chromosomal aberration, later a bcr/abl fusion gene, was identified as the main mechanism of disease development. Imatinib, the first clinically used tyrosine kinase inhibitor (TKI), proved to be remarkably effective for long-term CML control, and now TKIs have largely replaced HSCT, which was the only curative treatment method prior to their introduction into clinical practice. Presently, the survival of most patients with CML is the same as in general population. However, there are still some cases, in which common TKI therapy is ineffective. In some of them, 2nd and 3rd generation TKIs may be a solution. However, in acceleration phase (AP) and blast crisis (BC), HSCT still remain the method of choice.

An evolution of therapeutic approaches to CML is well illustrated by a review of current European LeukemiaNet (ELN) recommendations presented in this issue of CTT by the head of ELN, Prof. Dr. R. Hehlmann, who is one of the persons defining general strategy of CML treatment. This review specifically concerns second and higher-line TKI therapy in CML based on detection of additional chromosomal aberrations, minimal residual disease levels, previous therapies, and age-dependent comorbidities. These factors are also assessed to determine an individual risk for potential allo-HSCT recipients, when this treatment option is considered.

Also, this issue contains a description of single-center experience of HSCT and targeted therapies in patients with advanced-stage CML presented by Dr. Morozova E. et al. In this extensive cohort containing mainly patients with very unfavorable disease allo-HSCT still has an evident advantage over conservative approaches. Thus, it appears to be a positive answer to the key question posed by Prof. Gale: "Is there a future for hematopoietic cell transplantation?"

Transplantation aspects of blood malignancies are in focus of Cellular Therapy and Transplantation. Our potential authors from different clinics worldwide are invited to present their experience in novel treatments in hematological disorders, including immune and targeted therapy, role of HSCT (including genetically modified stem cells) in malignant and nonmalignant disorders.

Professor Alexander D. Kulagin, Editor-in-Chief, Cellular Therapy and Transplantation Journal


Is there a Future for Haematopoietic Cell Transplants?

Robert P. Gale            

Review articles

Clinical studies

The outcome of patients with advanced phase chronic myeloid leukemia with and without allogeneic hematopoietic stem cell transplantation

Elena V. Morozova, Yulia Yu. Vlasova, Maria V. Barabanshikova, Ksenia S. Jurovskaya, Tatyana V. Shneider, Tatyana L. Gindina, Ildar M. Barkhatov, Evgenij A. Bakin, Ivan S. Moiseev, Alexander D. Kulagin, Ludmila S. Zubarovskaya, Boris V. Afanasyev

Long-term goals in the treatment of chronic graft-versus-host disease after matched allogeneic hematopoietic stem cell transplantation

Ivan S. Moiseev, Anna A. Dotsenko, Anna G. Smirnova, Yulia Yu. Vlasova, Elena V. Morozova, Sergey N. Bondarenko, Boris V. Afanasyev

Risk factors for graft failure in allogeneic hematopoietic stem cell transplantation: a single-center study

Igor Novitzky-Basso1, Eshrak Al-Shaibani1, Mats Remberger2, Carol Chen1, Wilson Lam1, Arjun D. Law1, Ivan Pasic1, Fotios V. Michelis1, Auro Viswabandya1, Dennis D. Kim1, Jeffrey H. Lipton1, Armin Gerbitz1, Jonas Mattsson1, Rajat Kumar1, Zeyad Al-Shaibani1

Fanconi Anemia in the Czech Republic: role of HSCT and long-term follow-up

Petr Sedlacek, Petra Keslova, Petr Smisek, Martina Sukova, Marcela Malikova, Spiros Tavandzis, Jaroslav Cermak, Jan Stary

Donor-specific anti-HLA antibodies detection by de facto crossmatch method in pediatric recipients before haploidentical hematopoetic stem cell transplantation

Olesya V. Paina1, Irina E. Pavlova1,2, Natalia E. Ivanova1, Alexander L. Alyanskiy1, Tatiana A. Bykova1, Ludmila S. Zubarovskaya1, Alexander D. Kulagin1, Boris V. Afanasyev1

Experimental studies

Biomimetics for treatment of endometrial pathologies: an overview

Maria V. Konovalova1, Daria S. Tsaregorodtseva1,2, Rimma A. Poltavtseva3, Elena V. Svirshchevskaya1,3

Morphology of target drug delivery systems (CaCO3 vaterites covered with dextran sulfate) in rat muscular tissue

Pavel V. Popryadukhin1, Natalia N. Sudareva1,2, Оlga М. Suvorova1, Galina Yu. Yukina2, Еlena G. Sukhorukova2, Natalia N. Saprykina1, Ilya A. Barsuk3, Oleg V. Galibin2, Aleksandr D. Vilesov1,2

Letter to the Editor

Not all T cells are created alike!

Manuel Abecasis